Despite this, the therapeutic landscape has undergone a paradigm shift in recent years, with the introduction of new systemic treatment options that challenge the hegemony of T-DM1 as standard second-line therapy in advanced HER2+ BC. The gene discussed is ERBB2; the disease is breast cancer.